Physician profile
Mark S Devore
NPI 1578521217
$22,708.52
in general payments reported to CMS, 2019-2025
45 companies · $4,305 in 2025
The $4,305 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,014 · 2020: $1,461 · 2021: $2,842 · 2022: $3,703 · 2023: $4,045 · 2024: $3,338 · 2025: $4,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,488.10 |
| Education | $200.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,573.71 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $4,696.95 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $2,422.27 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $1,122.81 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,012.10 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $835.74 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $638.54 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $502.31 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $445.64 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $402.91 | 2020-2025 | Sucraid, Sucraid |
| Pfizer INC. | $374.54 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $366.35 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $356.98 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $330.30 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $281.66 | 2019-2025 | Linzess |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $258.96 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $241.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $237.27 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $195.49 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $165.24 | 2020-2023 | Talicia |
| Ardelyx, INC. | $152.53 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $138.95 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $92.94 | 2019-2023 | Sutab, Suflave |
| Amgen INC. | $79.74 | 2023 | Amjevita, Avsola |
| Shire North American Group INC | $78.12 | 2019 | |
| Phathom Pharmaceuticals, INC. | $75.80 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $69.12 | 2021-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $66.74 | 2021-2022 | |
| Organon LLC | $63.56 | 2023 | Hadlima, Renflexis |
| Ucb, INC. | $47.53 | 2019 | |
| Sandoz INC. | $43.84 | 2023-2024 | Hyrimoz |
| Daiichi Sankyo INC. | $42.72 | 2022-2023 | Injectafer |
| Cook Medical LLC | $40.96 | 2020-2023 | Fusion |
| Vivus LLC | $36.06 | 2023-2025 | Qsymia |
| Welch Allyn | $34.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $31.31 | 2024 | Andexxa |
| Mylan Institutional INC. | $26.12 | 2023 | Hulio |
| Novo Nordisk INC | $23.56 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2023 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $15.79 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $15.07 | 2019 | |
| Tersera Therapeutics LLC | $14.15 | 2025 | Xermelo |
| Evoke Pharma, INC. | $13.16 | 2020 | |
| Ibsa Pharma INC. | $12.06 | 2021 | |
| Alfasigma USA, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Devore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.